Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956414 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2LRRK2GRM5NPC1 | |
| SCHEMBL29951146 | 0.81 | CCR1 (0.33) | NOS2NOS3ALDH1A1MAPT | |
| SCHEMBL16225239 | 0.81 | CCR1 (0.33) | NOS2NOS3ALDH1A1MAPT | |
| SCHEMBL22121997 | 0.75 | KDM4E (0.37) | HPGDSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL16231386 | 0.75 | HPGD (0.50) | HPGDSMN1; SMN2LRRK2GRM5NPC1 | |
| SCHEMBL17473788 | 0.74 | L3MBTL1 (0.46) | HPGDSMN1; SMN2TSHRALDH1A1L3MBTL1 | |
| SCHEMBL16110848 | 0.72 | CCR1 (0.38) | NOS2NOS3 | |
| SCHEMBL29954504 | 0.72 | CCR1 (0.38) | NOS2NOS3 | |
| SCHEMBL12903576 | 0.72 | HPGD (0.47) | HPGDSMN1; SMN2LRRK2GRM5NPC1 | |
| SCHEMBL5942693 | 0.72 | HPGD (0.47) | HPGDSMN1; SMN2LRRK2GRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-2994469-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2994469-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | Gilead Sciences, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014182929-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HPGD 3657/4885SMN1; SMN2 3348/4885LRRK2 401/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HPGD 1609/4885SMN1; SMN2 4847/4885LRRK2 1737/4885 |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | HPGD 3657/4885SMN1; SMN2 3348/4885LRRK2 401/4885 |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HPGD 3587/4885SMN1; SMN2 3400/4885LRRK2 363/4885 |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HPGD 3657/4885SMN1; SMN2 3348/4885LRRK2 401/4885 |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HPGD 3573/4885SMN1; SMN2 3385/4885LRRK2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.